Codiak BioSciences' Engineered Exosome Candidates Show Early Antitumor Activity

Codiak BioSciences Inc CDAK announced platform-validating clinical data from Phase 1 trials of exoSTING and exoIL-12, and it plans to advance both candidates into Phase 2 trials.
In an open-label Phase 1 trial, exoIL-12 demonstrated a differentiating favorable safety and tolerability profile, with no detectable systemic exposure of IL-12 and no treatment-related adverse events.
The two patients with cutaneous T cell lymphoma who have been treated each received multiple injections of exoIL-12 and experienced tumor regressions in both injected and non-injected lesions, including a partial response in one patient.
Read Next: Codiak BioSciences's Pan Beta-Coronavirus Vaccine Shows Encouraging Action In Animal Studies.
In the Phase 1/2 trial of exoSTING in late-stage refractory solid tumors, data across all five dose cohorts showed that repeat doses of exoSTING were well-tolerated and demonstrated tumor retention with no systemic exposure of the STING agonist.
In a subset of patients, tumor shrinkage was observed in injected and uninjected lesions.
Price Action: CDAK shares traded lower by 16.2% at $3.05 on the last check Thursday.